BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-881. [PMID: 19558997 DOI: 10.1016/j.cgh.2009.01.004] [Cited by in Crossref: 345] [Cited by in F6Publishing: 314] [Article Influence: 26.5] [Reference Citation Analysis]
Number Citing Articles
1 Aubin F, Carbonnel F, Wendling D. The complexity of adverse side-effects to biological agents. Journal of Crohn's and Colitis 2013;7:257-62. [DOI: 10.1016/j.crohns.2012.06.024] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
2 Strik AS, van den Brink GR, Ponsioen C, Mathot R, Löwenberg M, D'haens GR. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2017;45:1128-34. [DOI: 10.1111/apt.13994] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 14.8] [Reference Citation Analysis]
3 Chupin A, Perduca V, Meyer A, Bellanger C, Carbonnel F, Dong C. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:1289-97. [PMID: 32840893 DOI: 10.1111/apt.16050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
4 Daugherty TT, Swerlick RA. Clinical context for cancer risk of immunosuppressive agents used in dermatology. Dermatol Ther 2021;34:e14433. [PMID: 33084077 DOI: 10.1111/dth.14433] [Reference Citation Analysis]
5 Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854 [PMID: 23002356 DOI: 10.3748/wjg.v18.i35.4823] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
6 Bollegala N, Jackson TD, Nguyen GC. Increased Postoperative Mortality and Complications Among Elderly Patients With Inflammatory Bowel Diseases: An Analysis of the National Surgical Quality Improvement Program Cohort. Clin Gastroenterol Hepatol 2016;14:1274-81. [PMID: 26656299 DOI: 10.1016/j.cgh.2015.11.012] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
7 Chang S, Hudesman D. First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician. Curr Gastroenterol Rep 2020;22:7. [PMID: 32002688 DOI: 10.1007/s11894-020-0745-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
8 Strik AS, Bots SJA, D’haens G, Löwenberg M. Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease. Expert Review of Clinical Pharmacology 2015;9:429-39. [DOI: 10.1586/17512433.2016.1133288] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
9 Levesque BG, Loftus EV. Medical Management of Ulcerative Colitis: Conventional Therapy—Azathioprine. In: Baumgart DC, editor. Crohn's Disease and Ulcerative Colitis. Cham: Springer International Publishing; 2017. pp. 413-9. [DOI: 10.1007/978-3-319-33703-6_40] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Golder S, Loke YK, Bland M. Comparison of pooled risk estimates for adverse effects from different observational study designs: methodological overview. PLoS One 2013;8:e71813. [PMID: 23977151 DOI: 10.1371/journal.pone.0071813] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
11 Velayos F. Managing risks of neoplasia in inflammatory bowel disease. Curr Gastroenterol Rep. 2012;14:174-180. [PMID: 22359106 DOI: 10.1007/s11894-012-0247-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
12 Vetro C, Bonanno G, Giulietti G, Romano A, Conticello C, Chiarenza A, Spina P, Coppolino F, Cunsolo R, Raimondo FD. Rare gastrointestinal lymphomas: The endoscopic investigation. World J Gastrointest Endosc 2015; 7(10): 928-949 [PMID: 26265987 DOI: 10.4253/wjge.v7.i10.928] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
13 Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Aliment Pharmacol Ther 2014;39:459-77. [PMID: 24405149 DOI: 10.1111/apt.12616] [Cited by in Crossref: 97] [Cited by in F6Publishing: 82] [Article Influence: 12.1] [Reference Citation Analysis]
14 Garg SK, Velayos FS, Kisiel JB. Intestinal and Nonintestinal Cancer Risks for Patients with Crohn's Disease. Gastroenterol Clin North Am. 2017;46:515-529. [PMID: 28838412 DOI: 10.1016/j.gtc.2017.05.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
15 Tun GS, Lobo AJ. Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn’s disease. Expert Opinion on Drug Metabolism & Toxicology 2014;11:317-27. [DOI: 10.1517/17425255.2015.995166] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
16 Bern EM, O’brien RF. Is it an eating disorder, gastrointestinal disorder, or both? Current Opinion in Pediatrics 2013;25:463-70. [DOI: 10.1097/mop.0b013e328362d1ad] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
17 Alvisi P, Dipasquale V, Barabino A, Martellossi S, Miele E, Lionetti P, Lombardi G, Cucchiara S, Torre G, Romano C. Infections and malignancies risks related to TNF-α-blocking agents in pediatric inflammatory bowel diseases. Expert Rev Gastroenterol Hepatol 2019;13:957-61. [PMID: 31490707 DOI: 10.1080/17474124.2019.1663173] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Bak M, Jess T, Flachs EM, Zwisler AD, Juel K, Frederiksen H. Risk of Inflammatory Bowel Disease in Patients with Chronic Myeloproliferative Neoplasms: A Danish Nationwide Cohort Study. Cancers (Basel) 2020;12:E2700. [PMID: 32967227 DOI: 10.3390/cancers12092700] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Siegel CA. Review article: explaining risks of inflammatory bowel disease therapy to patients: Review: communicating risks of IBD therapy. Alimentary Pharmacology & Therapeutics 2011;33:23-32. [DOI: 10.1111/j.1365-2036.2010.04489.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 6.0] [Reference Citation Analysis]
20 Ferreri AJ, Govi S, Pileri SA. Hepatosplenic gamma-delta T-cell lymphoma. Crit Rev Oncol Hematol. 2012;83:283-292. [PMID: 22047938 DOI: 10.1016/j.critrevonc.2011.10.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
21 Khanna R, Feagan BG. Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events. Expert Opinion on Drug Safety 2015;14:987-97. [DOI: 10.1517/14740338.2015.1029915] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
22 Biancone L, Onali S, Petruzziello C, Calabrese E, Pallone F. Cancer and immunomodulators in inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21:674-698. [PMID: 25545375 DOI: 10.1097/mib.0000000000000243] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
23 Mulat BB, Boroda K, Guddati H, Kiyici N. Primary Diffuse Large B-Cell Lymphoma of the Rectosigmoid Colon in a Patient With Ulcerative Colitis Who Never Received Immunosuppression. ACG Case Rep J 2020;7:e00490. [PMID: 34476268 DOI: 10.14309/crj.0000000000000490] [Reference Citation Analysis]
24 Tarella C, Gueli A, Ruella M, Cignetti A. Lymphocyte transformation and autoimmune disorders. Autoimmunity Reviews 2013;12:802-13. [DOI: 10.1016/j.autrev.2012.11.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
25 Chen L, Xu CJ, Wu W, Ding BJ, Liu ZJ. Anti-TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta-analysis. J Dig Dis 2021;22:408-18. [PMID: 34048629 DOI: 10.1111/1751-2980.13026] [Reference Citation Analysis]
26 Grevenitis P, Thomas A, Lodhia N. Medical Therapy for Inflammatory Bowel Disease. Surgical Clinics of North America 2015;95:1159-82. [DOI: 10.1016/j.suc.2015.08.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
27 Severyns T, Kirchgesner J, Lambert J, Thieblemont C, Amiot A, Abitbol V, Treton X, Cazals-Hatem D, Malamut G, Coppo P, Galicier L, Walter-Petrich A, Deau-Fischer B, Besson C, Aparicio T, Beaugerie L, Allez M, Gornet JM. Prognosis of Lymphoma in Patients With Known Inflammatory Bowel Disease: A French Multicentre Cohort Study. J Crohns Colitis 2020;14:1222-30. [PMID: 32161943 DOI: 10.1093/ecco-jcc/jjaa048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Di Domenicantonio R, Trotta F, Cascini S, Agabiti N, Kohn A, Gasbarrini A, Davoli M, Addis A. Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. Clin Epidemiol 2018;10:203-13. [PMID: 29440933 DOI: 10.2147/CLEP.S150030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
29 Sifuentes H, Kane S. Monitoring for Extra-Intestinal Cancers in IBD. Curr Gastroenterol Rep 2015;17. [DOI: 10.1007/s11894-015-0467-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
30 Na SY, Moon W. Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease. Gut Liver. 2019;13:604-616. [PMID: 31195433 DOI: 10.5009/gnl19019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
31 Törüner M, Akpınar H, Akyüz F, Dağlı Ü, Över Hamzaoğlu H, Tezel A, Ünsal B, Yıldırım S, Çelik AF. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019;30:S913-46. [PMID: 32207688 DOI: 10.5152/tjg.2019.061119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Ali T, Madhoun MF, Bronze M, Yun L, Shapiro D. Viral Infections in Patients With Inflammatory Bowel Disease on Immunosuppressants. The American Journal of the Medical Sciences 2012;343:227-32. [DOI: 10.1097/maj.0b013e31821ff728] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
33 Nuti F, Civitelli F, Cucchiara S. Long-Term Safety of Immunomodulators in Pediatric Inflammatory Diseases. Pediatr Drugs 2014;16:343-52. [DOI: 10.1007/s40272-014-0084-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
34 Smeets FGM, Liedorp PR, van der Poel M, Miclea RL, Masclee AAM, Pierik M. Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature. J Crohns Colitis 2019;13:1470-3. [PMID: 31116402 DOI: 10.1093/ecco-jcc/jjz084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
35 Chen Y, Sun J, Yang Y, Huang Y, Liu G. Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses. Clin Rheumatol 2016;35:1-18. [PMID: 26573205 DOI: 10.1007/s10067-015-3115-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
36 Hong SJ, Katz S. The elderly IBD patient in the modern era: changing paradigms in risk stratification and therapeutic management. Therap Adv Gastroenterol 2021;14:17562848211023399. [PMID: 34276809 DOI: 10.1177/17562848211023399] [Reference Citation Analysis]
37 Moran GW, Lim AW, Bailey JL, Dubeau MF, Leung Y, Devlin SM, Novak K, Kaplan GG, Iacucci M, Seow C. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:1002-1024. [PMID: 24099467 DOI: 10.1111/apt.12491] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
38 Ji N, Somanaboeina A, Dixit A, Kawamura K, Hayward NJ, Self C, Olson GL, Forsthuber TG. Small molecule inhibitor of antigen binding and presentation by HLA-DR2b as a therapeutic strategy for the treatment of multiple sclerosis. J Immunol 2013;191:5074-84. [PMID: 24123687 DOI: 10.4049/jimmunol.1300407] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
39 Dulai PS, Siegel CA, Dubinsky MC. Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2927-36. [PMID: 23867874 DOI: 10.1097/MIB.0b013e31829aad16] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
40 Cabriada JL, Vera I, Domènech E, Barreiro-de Acosta M, Esteve M, Gisbert JP, Panés J, Gomollón F; Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). [Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. Gastroenterol Hepatol 2013;36:127-46. [PMID: 23433780 DOI: 10.1016/j.gastrohep.2013.01.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
41 Trikudanathan G, Venkatesh PG, Navaneethan U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs. 2012;72:2333-2349. [PMID: 23181971 DOI: 10.2165/11638120-000000000-00000] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
42 Nielsen OH, Bjerrum JT, Herfarth H, Rogler G. Recent advances using immunomodulators for inflammatory bowel disease. J Clin Pharmacol. 2013;53:575-588. [PMID: 23408468 DOI: 10.1002/jcph.2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
43 Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720-727. [PMID: 26323879 DOI: 10.1038/nrgastro.2015.150] [Cited by in Crossref: 766] [Cited by in F6Publishing: 707] [Article Influence: 109.4] [Reference Citation Analysis]
44 Trivedi I, Hanauer SB. Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. Expert Opin Drug Saf 2015;14:1915-34. [PMID: 26559664 DOI: 10.1517/14740338.2015.1108961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
45 Ahmad H, Kumar VL. Pharmacotherapy of ulcerative colitis - current status and emerging trends. J Basic Clin Physiol Pharmacol 2018;29:581-92. [PMID: 30089097 DOI: 10.1515/jbcpp-2016-0014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
46 Fausel R, Afzali A. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists. Ther Clin Risk Manag 2015;11:63-73. [PMID: 25609972 DOI: 10.2147/TCRM.S55506] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
47 Dulai PS, Gleeson MW, Taylor D, Holubar SD, Buckey JC, Siegel CA. Systematic review: The safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:1266-1275. [PMID: 24738651 DOI: 10.1111/apt.12753] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
48 McLean LP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol 2014;8:223-40. [PMID: 24490595 DOI: 10.1586/17474124.2014.881715] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
49 Sebastian S, Neilaj S. Practical guidance for the management of inflammatory bowel disease in patients with cancer. Which treatment? Therap Adv Gastroenterol 2019;12:1756284818817293. [PMID: 30643542 DOI: 10.1177/1756284818817293] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
50 Nielsen OH. New strategies for treatment of inflammatory bowel disease. Front Med (Lausanne). 2014;1:3. [PMID: 25685754 DOI: 10.3389/fmed.2014.00003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
51 Stallmach A, Hagel S, Gharbi A, Settmacher U, Hartmann M, Schmidt C, Bruns T. Medical and surgical therapy of inflammatory bowel disease in the elderly - prospects and complications. J Crohns Colitis. 2011;5:177-188. [PMID: 21575879 DOI: 10.1016/j.crohns.2011.02.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
52 Yasunaga M. Antibody therapeutics and immunoregulation in cancer and autoimmune disease. Semin Cancer Biol 2020;64:1-12. [PMID: 31181267 DOI: 10.1016/j.semcancer.2019.06.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
53 Shelton E, Laharie D, Scott FI, Mamtani R, Lewis JD, Colombel JF, Ananthakrishnan AN. Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. Gastroenterology. 2016;151:97-109.e4. [PMID: 27039969 DOI: 10.1053/j.gastro.2016.03.037] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
54 Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537-545. [PMID: 26284562 DOI: 10.1038/nrgastro.2015.135] [Cited by in Crossref: 164] [Cited by in F6Publishing: 157] [Article Influence: 23.4] [Reference Citation Analysis]
55 Saliba L, Moulis G, Abou Taam M, Rousseau V, Chebane L, Petitpain N, Baldin B, Pugnet G, Montastruc J, Bagheri H. Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database. Fundam Clin Pharmacol 2016;30:162-71. [DOI: 10.1111/fcp.12171] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
56 Fischer M, Helper DJ, Chiorean MV. Myeloproliferative disorders in patients with inflammatory bowel disease on anti-TNF-α therapy: Report of two cases and review of the literature. Inflammatory Bowel Diseases 2011;17:674-5. [DOI: 10.1002/ibd.21291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
57 Dart RJ, Griffin N, Taylor K, Duncan J, Sastrillo M, Sanderson J, Irving PM. Reassessment of Crohn's disease treated with at least 12 months of anti-TNF therapy: how likely is treatment withdrawal? Frontline Gastroenterol 2014;5:176-82. [PMID: 28839767 DOI: 10.1136/flgastro-2013-100392] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
58 Lichtenstein GR, Rutgeerts P, Sandborn WJ, Sands BE, Diamond RH, Blank M, Montello J, Tang L, Cornillie F, Colombel JF. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1051-1063. [PMID: 22613901 DOI: 10.1038/ajg.2012.89] [Cited by in Crossref: 137] [Cited by in F6Publishing: 130] [Article Influence: 13.7] [Reference Citation Analysis]
59 Denmark VK, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update. Expert Review of Clinical Immunology 2014;9:77-92. [DOI: 10.1586/eci.12.91] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
60 Mottet C, Schoepfer AM, Juillerat P, Cosnes J, Froehlich F, Kessler-brondolo V, Seibold F, Rogler G, Vavricka SR, Michetti P. Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2016;22:2733-47. [DOI: 10.1097/mib.0000000000000923] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
61 Caprioli F, Daperno M, Bravatà I, Brigido A, Frigerio D, Secchi O, Rispo A. Who are the patients with Crohn's disease unsuitable to receive an anti-TNFα therapy? Results from a survey of Italian physicians and literature review. Eur J Gastroenterol Hepatol 2021;33:1082-90. [PMID: 34213505 DOI: 10.1097/MEG.0000000000002183] [Reference Citation Analysis]
62 Muehler A, Slizgi JR, Kohlhof H, Groeppel M, Peelen E, Vitt D. Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases. World J Gastrointest Pathophysiol 2020; 11(6): 114-130 [PMID: 33362939 DOI: 10.4291/wjgp.v11.i6.114] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Golder S, Loke YK. Failure or success of electronic search strategies to identify adverse effects data. J Med Libr Assoc 2012;100:130-4. [PMID: 22514510 DOI: 10.3163/1536-5050.100.2.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
64 Westbrook AM, Szakmary A, Schiestl RH. Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. Mutat Res. 2010;705:40-59. [PMID: 20298806 DOI: 10.1016/j.mrrev.2010.03.001] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 6.3] [Reference Citation Analysis]
65 Wang L, Zhu B, Deng Y, Li T, Tian Q, Yuan Z, Ma L, Cheng C, Guo Q, Qiu L. Biocatalytic and Antioxidant Nanostructures for ROS Scavenging and Biotherapeutics. Adv Funct Mater 2021;31:2101804. [DOI: 10.1002/adfm.202101804] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
66 Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics 2019;13:139-78. [PMID: 31440029 DOI: 10.2147/BTT.S207246] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
67 Axelrad JE, Fowler SA, Friedman S, Ananthakrishnan AN, Yajnik V. Effects of cancer treatment on inflammatory bowel disease remission and reactivation. Clin Gastroenterol Hepatol. 2012;10:1021-1027.e1. [PMID: 22732273 DOI: 10.1016/j.cgh.2012.06.016] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
68 Llanos-Chea A, Shapiro JM, Winter RW, Jerger L, Menz T, Gibson M, Friedmann AM, Treaba D, Papamichael K, Cheifetz AS, Friedman S, Hamilton MJ, Winter HS. Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series. Dig Dis Sci 2021. [PMID: 33595782 DOI: 10.1007/s10620-021-06884-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Zaltman C, Amarante H, Brenner MM, Costa MHM, Flores C, Leal RF, Grain JFS, Zeroncio M. Crohn's disease - treatment with biological medication. Rev Assoc Med Bras (1992) 2019;65:554-67. [PMID: 31066809 DOI: 10.1590/1806-9282.65.4.554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
70 Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED. T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013;108:99-105. [PMID: 23032984 DOI: 10.1038/ajg.2012.334] [Cited by in Crossref: 142] [Cited by in F6Publishing: 120] [Article Influence: 14.2] [Reference Citation Analysis]
71 John ES, Katz K, Saxena M, Chokhavatia S, Katz S. Management of Inflammatory Bowel Disease in the Elderly. Curr Treat Options Gastroenterol. 2016;14:285-304. [PMID: 27387455 DOI: 10.1007/s11938-016-0099-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
72 Stidham RW, Guentner AS, Ruma JL, Govani SM, Waljee AK, Higgins PD. Intestinal Dilation and Platelet:Albumin Ratio Are Predictors of Surgery in Stricturing Small Bowel Crohn's Disease. Clin Gastroenterol Hepatol 2016;14:1112-1119.e2. [PMID: 27155551 DOI: 10.1016/j.cgh.2016.04.033] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
73 Kang B, Choe YH. Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target. Pediatr Gastroenterol Hepatol Nutr 2018;21:1-11. [PMID: 29383299 DOI: 10.5223/pghn.2018.21.1.1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
74 Lewis JD, Scott FI, Brensinger CM, Roy JA, Osterman MT, Mamtani R, Bewtra M, Chen L, Yun H, Xie F, Curtis JR. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease. Am J Gastroenterol 2018;113:405-17. [PMID: 29336432 DOI: 10.1038/ajg.2017.479] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 13.5] [Reference Citation Analysis]
75 Xu Z, Davis HM, Zhou H. Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety. J Clin Pharmacol 2015;55 Suppl 3:S60-74. [PMID: 25707965 DOI: 10.1002/jcph.380] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
76 Zheng S, Xu H, Ouyang Q, Xue L, Zhang Y, Cui D. A case of rapid growing colonic NK/T cell lymphoma complicated by Crohn's disease. Chin J Cancer Res 2013;25:119-23. [PMID: 23372350 DOI: 10.3978/j.issn.1000-9604.2012.12.06] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
77 Quezada SM, Mclean LP, Cross RK. Adverse events in IBD therapy: the 2018 update. Expert Review of Gastroenterology & Hepatology 2018;12:1183-91. [DOI: 10.1080/17474124.2018.1545574] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
78 Kalman RS, Hartshorn K, Farraye FA. Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD. Inflamm Bowel Dis 2015;21:428-35. [PMID: 25251059 DOI: 10.1097/MIB.0000000000000211] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
79 Mañosa M, Calafat M, de Francisco R, García C, Casanova MJ, Huelín P, Calvo M, Tosca J, Fernández-Salazar L, Arajol C, Zabana Y, Bastida G, Hinojosa J, Márquez L, Barreiro-de-Acosta M, Calvet X, Monfort D, Gómez-Garcia MR, Rodríguez E, Huguet JM, Rojas-Feria M, Hervias D, Atienza R, Busquets D, Zapata E, Dueñas C, Charro M, Martínez-Cerezo FJ, Plaza R, Vázquez JM, Gisbert JP, Cañete F, Cabré E, Domènech E; GETECCU. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study. Aliment Pharmacol Ther 2018;47:605-14. [PMID: 29369387 DOI: 10.1111/apt.14494] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
80 Shivaji UN, Sharratt CL, Thomas T, Smith SCL, Iacucci M, Moran GW, Ghosh S, Bhala N. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2019;49:664-80. [DOI: 10.1111/apt.15097] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
81 Simčič S, Berlec A, Stopinšek S, Štrukelj B, Orel R. Engineered and wild-type L. lactis promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient's mucosa. World J Microbiol Biotechnol 2019;35:45. [PMID: 30810891 DOI: 10.1007/s11274-019-2615-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
82 Seow CH, de Silva S, Kaplan GG, Devlin SM, Ghosh S, Panaccione R. Managing the risks of IBD therapy. Curr Gastroenterol Rep 2009;11:509-17. [PMID: 19903428 DOI: 10.1007/s11894-009-0077-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
83 Park J, Cheon JH. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease. Gut Liver 2018;12:623-32. [PMID: 29788675 DOI: 10.5009/gnl17462] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
84 Lopetuso LR, Petito V, Zinicola T, Graziani C, Gerardi V, Arena V, Caristo ME, Poscia A, Cammarota G, Papa A, Cufino V, Sgambato A, Gasbarrini A, Scaldaferri F. Infliximab does not increase colonic cancer risk associated to murine chronic colitis. World J Gastroenterol 2016; 22(44): 9727-9733 [PMID: 27956796 DOI: 10.3748/wjg.v22.i44.9727] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
85 Jones JL, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY, Tanyingoh D, Raffals L, Irving P, Kozuch P, Sparrow M, Velayos F, Bressler B, Cheifetz A, Colombel JF, Siegel CA. Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials. Clin Gastroenterol Hepatol 2015;13:2233-40.e1-2; quiz e177-8. [PMID: 26142167 DOI: 10.1016/j.cgh.2015.06.034] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 11.1] [Reference Citation Analysis]
86 Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, Elmunzer BJ, Saini SD, Vijan S, Waljee AK. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014;39:1349-1362. [PMID: 24749763 DOI: 10.1111/apt.12749] [Cited by in Crossref: 107] [Cited by in F6Publishing: 98] [Article Influence: 13.4] [Reference Citation Analysis]
87 Nieminen U, Färkkilä M. Malignancies in inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2014;50:81-9. [DOI: 10.3109/00365521.2014.992041] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
88 Ashworth LA, Billett A, Mitchell P, Nuti F, Siegel C, Bousvaros A. Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort. Inflamm Bowel Dis. 2012;18:838-843. [PMID: 21887728 DOI: 10.1002/ibd.21844] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
89 Lakatos PL, Lovasz BD, David G, Pandur T, Erdelyi Z, Mester G, Balogh M, Szipocs I, Molnar C, Komaromi E, Golovics PA, Vegh Z, Mandel M, Horvath A, Szathmari M, Kiss LS, Lakatos L. The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe. J Crohns Colitis 2013;7:385-91. [PMID: 22766526 DOI: 10.1016/j.crohns.2012.06.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
90 Chauvin A, Le Thuaut A, Belhassan M, Le Baleur Y, Mesli F, Bastuji-Garin S, Delchier JC, Amiot A. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn’s disease: A retrospective study. Dig Liver Dis. 2014;46:695-700. [PMID: 24893686 DOI: 10.1016/j.dld.2014.04.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
91 Roblin X, Boschetti G, Williet N, Nancey S, Marotte H, Berger A, Phelip JM, Peyrin-biroulet L, Colombel JF, Del Tedesco E, Paul S, Flourie B. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. Aliment Pharmacol Ther 2017;46:142-9. [DOI: 10.1111/apt.14106] [Cited by in Crossref: 64] [Cited by in F6Publishing: 52] [Article Influence: 12.8] [Reference Citation Analysis]
92 Scott FI, Osterman MT, McConnell RA, Lorusso M, Aberra F, Kerner C, Lichtenstein GR, Lewis JD. Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model. Inflamm Bowel Dis 2013;19:2625-33. [PMID: 24108113 DOI: 10.1097/01.MIB.0000437043.36338.21] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
93 Griffey RT, Fowler KJ, Theilen A, Gutierrez A. Considerations in Imaging Among Emergency Department Patients With Inflammatory Bowel Disease. Ann Emerg Med 2017;69:587-99. [PMID: 27317304 DOI: 10.1016/j.annemergmed.2016.04.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
94 Afif W, Sandborn WJ, Faubion WA, Rahman M, Harmsen SW, Zinsmeister AR, Loftus EV. Risk Factors for Lymphoma in Patients with Inflammatory Bowel Disease: A Case-control Study. Inflammatory Bowel Diseases 2013;19:1384-9. [DOI: 10.1097/mib.0b013e318281325e] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
95 Hyams JS, Dubinsky MC, Baldassano RN, Colletti RB, Cucchiara S, Escher J, Faubion W, Fell J, Gold BD, Griffiths A. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. Gastroenterology. 2017;152:1901-1914.e3. [PMID: 28193515 DOI: 10.1053/j.gastro.2017.02.004] [Cited by in Crossref: 114] [Cited by in F6Publishing: 95] [Article Influence: 22.8] [Reference Citation Analysis]
96 Taleban S, Colombel JF, Mohler MJ, Fain MJ. Inflammatory bowel disease and the elderly: a review. J Crohns Colitis. 2015;9:507-515. [PMID: 25870198 DOI: 10.1093/ecco-jcc/jjv059] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 10.1] [Reference Citation Analysis]
97 Bern EM, Bousvaros A. Loss of response to biologics versus increased risk of lymphoma in children with inflammatory bowel disease: the clinician’s conundrum. Expert Review of Clinical Immunology 2014;9:117-27. [DOI: 10.1586/eci.12.97] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
98 Yadav S, Singh S, Harmsen WS, Edakkanambeth Varayil J, Tremaine WJ, Loftus EV Jr. Effect of Medications on Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Population-Based Cohort Study from Olmsted County, Minnesota. Mayo Clin Proc 2015;90:738-46. [PMID: 25963756 DOI: 10.1016/j.mayocp.2015.03.024] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
99 Chen Y, Friedman M, Liu G, Deodhar A, Chu CQ. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders? Cytokine 2018;101:78-88. [PMID: 27688201 DOI: 10.1016/j.cyto.2016.09.013] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
100 Rodriguez AA, Kerner J, Luna-Fineman S, Berry GJ. Hodgkin lymphoma following adalimumab for the treatment of Crohn’s disease in an adolescent. Dig Dis Sci. 2014;59:2403-2405. [PMID: 24817339 DOI: 10.1007/s10620-014-3191-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
101 Pittet V, Froehlich F, Maillard MH, Mottet C, Gonvers JJ, Felley C, Vader JP, Burnand B, Michetti P, Schoepfer A. When do we dare to stop biological or immunomodulatory therapy for Crohn’s disease? Results of a multidisciplinary European expert panel. J Crohns Colitis. 2013;7:820-826. [PMID: 23664620 DOI: 10.1016/j.crohns.2013.04.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
102 Yamamoto-Furusho JK, Bosques-Padilla F, Daffra P, De Paula JA, Etchevers J, Galiano MT, Ibañez P, Juliao F, Kotze PG, Marroquín de la Garza JM, Monreal Robles R, Rocha JL, Steinwurz F, Vázquez-Frías R, Veitia G, Zaltman C. Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part). Rev Gastroenterol Mex 2017;82:134-55. [PMID: 28318706 DOI: 10.1016/j.rgmx.2016.07.005] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
103 Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017;52:141-150. [PMID: 27832357 DOI: 10.1007/s00535-016-1283-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
104 Ardizzone S, Cassinotti A, de Franchis R. Immunosuppressive and biologic therapy for ulcerative colitis. Expert Opinion on Emerging Drugs 2012;17:449-67. [DOI: 10.1517/14728214.2012.744820] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
105 Renna S, Cottone M, Orlando A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol 2014; 20(29): 9675-9690 [PMID: 25110407 DOI: 10.3748/wjg.v20.i29.9675] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
106 Vetro C, Romano A, Amico I, Conticello C, Motta G, Figuera A, Chiarenza A, Raimondo CD, Giulietti G, Bonanno G, Palumbo GA, Raimondo FD. Endoscopic features of gastro-intestinal lymphomas: From diagnosis to follow-up. World J Gastroenterol 2014; 20(36): 12993-13005 [PMID: 25278693 DOI: 10.3748/wjg.v20.i36.12993] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
107 El Mourabet M, Hashash JG, Sun NH, Issa M, Katz JA, Regueiro M, Barrie AM 3rd, Baidoo L, Schwartz MB, Swoger JM, Levesque MC, Binion DG. Clinical course of Crohn's disease following treatment of lymphoma. Inflamm Bowel Dis 2011;17:1265-9. [PMID: 21351199 DOI: 10.1002/ibd.21487] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
108 D'haens G, Rutgeerts P. Immunosuppression-associated lymphoma in IBD. The Lancet 2009;374:1572-3. [DOI: 10.1016/s0140-6736(09)61487-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
109 Burmester GR, Gordon KB, Rosenbaum JT, Arikan D, Lau WL, Li P, Faccin F, Panaccione R. Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. Adv Ther 2020;37:364-80. [PMID: 31748904 DOI: 10.1007/s12325-019-01145-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
110 Biancone L, Armuzzi A, Scribano ML, D’inca R, Castiglione F, Papi C, Angelucci E, Daperno M, Mocciaro F, Riegler G, Fries W, Meucci G, Alvisi P, Spina L, Ardizzone S, Petruzziello C, Ruffa A, Kohn A, Vecchi M, Guidi L, Di Mitri R, Renna S, Emma C, Rogai F, Rossi A, Orlando A, Pallone F; on behalf of the Italian Group for the study of Inflammatory Bowel Disease. Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. ECCOJC 2016;10:913-24. [DOI: 10.1093/ecco-jcc/jjw048] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
111 Chen J, Andrews JM, Kariyawasam V, Moran N, Gounder P, Collins G, Walsh AJ, Connor S, Lee TWT, Koh CE, Chang J, Paramsothy S, Tattersall S, Lemberg DA, Radford-smith G, Lawrance IC, Mclachlan A, Moore GT, Corte C, Katelaris P, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: acute severe ulcerative colitis - evidence-based consensus statements. Aliment Pharmacol Ther 2016;44:127-44. [DOI: 10.1111/apt.13670] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
112 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 184] [Cited by in F6Publishing: 166] [Article Influence: 46.0] [Reference Citation Analysis]
113 Segal JP, Htet HMT, Limdi J, Hayee B. How to manage IBD in the 'elderly'. Frontline Gastroenterol 2020;11:468-77. [PMID: 33101625 DOI: 10.1136/flgastro-2019-101218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
114 Bewtra M, Johnson FR. Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data. Patient 2013;6:241-55. [PMID: 24127239 DOI: 10.1007/s40271-013-0031-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
115 Dignass A, Akbar A, Hart A, Subramanian S, Bommelaer G, Baumgart DC, Grimaud JC, Cadiot G, Makins R, Hoque S, Bouguen G, Bonaz B. Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. J Crohns Colitis. 2016;10:812-820. [PMID: 26818659 DOI: 10.1093/ecco-jcc/jjw032] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
116 Towbin AJ, Sullivan J, Denson LA, Wallihan DB, Podberesky DJ. CT and MR enterography in children and adolescents with inflammatory bowel disease. Radiographics. 2013;33:1843-1860. [PMID: 24224581 DOI: 10.1148/rg.337105140] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
117 Hedin C, Halfvarson J. Should we use vedolizumab as mono or combo therapy in ulcerative colitis?Best Pract Res Clin Gastroenterol. 2018;32-33:27-34. [PMID: 30060935 DOI: 10.1016/j.bpg.2018.05.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
118 Molander P, Färkkilä M, Kemppainen H, Blomster T, Jussila A, Mustonen H, Sipponen T. Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents. Scandinavian Journal of Gastroenterology 2017;52:284-90. [DOI: 10.1080/00365521.2016.1250942] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
119 Lapsia S, Koganti S, Spadaro S, Rajapakse R, Chawla A, Bhaduri-McIntosh S. Anti-TNFα therapy for inflammatory bowel diseases is associated with Epstein-Barr virus lytic activation. J Med Virol 2016;88:312-8. [PMID: 26307954 DOI: 10.1002/jmv.24331] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
120 Di Sabatino A, Liberato L, Marchetti M, Biancheri P, Corazza GR. Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. Intern Emerg Med. 2011;6 Suppl 1:17-27. [PMID: 22009609 DOI: 10.1007/s11739-011-0673-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
121 Beaugerie L. Immunosuppression-related lymphomas and cancers in IBD: how can they be prevented? Dig Dis. 2012;30:415-419. [PMID: 22796808 DOI: 10.1159/000338144] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
122 Bell GM, Reynolds G, Isaacs JD. Biologic therapies in non-rheumatic diseases: lessons for rheumatologists? Nat Rev Rheumatol 2011;7:507-16. [PMID: 21808288 DOI: 10.1038/nrrheum.2011.106] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
123 Chumanevich AA, Chaparala A, Witalison EE, Tashkandi H, Hofseth AB, Lane C, Pena E, Liu P, Pittman DL, Nagarkatti P, Nagarkatti M, Hofseth LJ, Chumanevich AA. Looking for the best anti-colitis medicine: A comparative analysis of current and prospective compounds. Oncotarget 2017;8:228-37. [PMID: 27974688 DOI: 10.18632/oncotarget.13894] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
124 Sturm A, Maaser C, Mendall M, Karagiannis D, Karatzas P, Ipenburg N, Sebastian S, Rizzello F, Limdi J, Katsanos K, Schmidt C, Jeuring S, Colombo F, Gionchetti P. European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly. J Crohns Colitis 2017;11:263-73. [PMID: 27797918 DOI: 10.1093/ecco-jcc/jjw188] [Cited by in Crossref: 16] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
125 Weimers P, Munkholm P. The Natural History of IBD: Lessons Learned. Curr Treat Options Gastroenterol 2018;16:101-11. [PMID: 29359275 DOI: 10.1007/s11938-018-0173-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
126 Sparrow MP, Melmed GY, Devlin S, Kozuch P, Raffals L, Loftus Jr EV, Rubin DT, Spiegel B, Baidoo L, Bressler B, Cheifetz A, Irving P, Jones J, Kaplan GG, Velayos F, Siegel CA. De‐escalating medical therapy in Crohn’s disease patients who are in deep remission: A RAND appropriateness panel. GastroHep 2019;1:108-17. [DOI: 10.1002/ygh2.337] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Devlin SM, Cheifetz AS, Siegel CA. Patient-Specific Approach to Combination Versus Monotherapy with the Use of Antitumor Necrosis Factor α Agents for Inflammatory Bowel Disease. Gastroenterology Clinics of North America 2012;41:411-28. [DOI: 10.1016/j.gtc.2012.01.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
128 Benchimol EI, Cook SF, Erichsen R, Long MD, Bernstein CN, Wong J, Carroll CF, Frøslev T, Sampson T, Kappelman MD. International variation in medication prescription rates among elderly patients with inflammatory bowel disease. Journal of Crohn's and Colitis 2013;7:878-89. [DOI: 10.1016/j.crohns.2012.09.001] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
129 Bewtra M. Lymphoma in Inflammatory Bowel Disease and Treatment Decisions. American Journal of Gastroenterology 2012;107:964-70. [DOI: 10.1038/ajg.2011.479] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
130 Molander P, Färkkilä M, Salminen K, Kemppainen H, Blomster T, Koskela R, Jussila A, Rautiainen H, Nissinen M, Haapamäki J. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission. Inflamm Bowel Dis. 2014;20:1021-1028. [PMID: 24798636 DOI: 10.1097/mib.0000000000000052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis]
131 Lam GY, Halloran BP, Peters AC, Fedorak RN. Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders. World J Gastrointest Pathophysiol 2015; 6(4): 181-192 [PMID: 26600976 DOI: 10.4291/wjgp.v6.i4.181] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
132 Pudipeddi A, Kariyawasam V, Haifer C, Baraty B, Paramsothy S, Leong RW. Safety of drugs used for the treatment of Crohn’s disease. Expert Opinion on Drug Safety 2019;18:357-67. [DOI: 10.1080/14740338.2019.1612874] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
133 Rufo PA, Denson LA, Sylvester FA, Szigethy E, Sathya P, Lu Y, Wahbeh GT, Sena LM, Faubion WA. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr. 2012;55:93-108. [PMID: 22516861 DOI: 10.1097/mpg.0b013e31825959b8] [Cited by in Crossref: 70] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
134 Shah R, Kellermayer R. Microbiome associations of therapeutic enteral nutrition. Nutrients. 2014;6:5298-5311. [PMID: 25421531 DOI: 10.3390/nu6115298] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
135 de Silva S, Devlin S, Panaccione R. Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol 2010;7:93-101. [PMID: 20134491 DOI: 10.1038/nrgastro.2009.221] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
136 Blonski W, Buchner AM, Lichtenstein GR. Inflammatory bowel disease therapy: current state-of-the-art. Curr Opin Gastroenterol 2011;27:346-57. [PMID: 21654383 DOI: 10.1097/MOG.0b013e328347aef3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
137 Wilson JC, Furlano RI, Jick SS, Meier CR. A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease. J Gastroenterol 2016;51:1050-62. [PMID: 27056729 DOI: 10.1007/s00535-016-1199-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
138 Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, Dotan I, Chowers Y, Confino-Cohen R, Weiss B. Infliximab-Related Infusion Reactions: Systematic Review. J Crohns Colitis. 2015;9:806-815. [PMID: 26092578 DOI: 10.1093/ecco-jcc/jjv096] [Cited by in Crossref: 97] [Cited by in F6Publishing: 72] [Article Influence: 13.9] [Reference Citation Analysis]
139 Miyoshi J, Matsuura M, Hisamatsu T. Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis. Expert Opin Drug Saf 2021. [PMID: 34511011 DOI: 10.1080/14740338.2021.1980536] [Reference Citation Analysis]
140 Geller S, Xu H, Lebwohl M, Nardone B, Lacouture ME, Kheterpal M. Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update. Am J Clin Dermatol 2018;19:363-75. [PMID: 29260411 DOI: 10.1007/s40257-017-0337-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
141 Dahmus J, Rosario M, Clarke K. Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy. Clin Exp Gastroenterol 2020;13:339-50. [PMID: 32982364 DOI: 10.2147/CEG.S237646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
142 Cui D, Huang G, Yang D, Huang B, An B. Efficacy and safety of interferon-gamma-targeted therapy in Crohn's disease: a systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol 2013;37:507-13. [PMID: 23433962 DOI: 10.1016/j.clinre.2012.12.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
143 Ye BD. [Inflammatory bowel disease and lymphoproliferative disorders]. Korean J Gastroenterol 2011;58:171-7. [PMID: 22042416 DOI: 10.4166/kjg.2011.58.4.171] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
144 Kyriakos N, Papaefthymiou A, Giakoumis M, Iatropoulos G, Mantzaris G, Liatsos C. Informed consent in inflammatory bowel disease: a necessity in real-world clinical practice. Ann Gastroenterol 2021;34:466-75. [PMID: 34276184 DOI: 10.20524/aog.2021.0635] [Reference Citation Analysis]
145 Cappello M, Bravatà I, Cocorullo G, Cacciatore M, Florena AM. Splenic littoral cell hemangioendothelioma in a patient with Crohn's disease previously treated with immunomodulators and anti-TNF agents: a rare tumor linked to deep immunosuppression. Am J Gastroenterol 2011;106:1863-5. [PMID: 21979217 DOI: 10.1038/ajg.2011.204] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
146 Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs. 2010;24 Suppl 1:3-14. [PMID: 21175228 DOI: 10.2165/11586290-000000000-00000] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 5.1] [Reference Citation Analysis]
147 Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol. 2010;105:1142-1149. [PMID: 20389296 DOI: 10.1038/ajg.2010.158] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 5.8] [Reference Citation Analysis]
148 Maira González N, Scocco S, Estepa R. [Hodgkin's lymphoma associated with inflammatory bowel disease treated with thiopurines. A case report and review of the literature]. Rev Esp Patol 2019;52:242-5. [PMID: 31530407 DOI: 10.1016/j.patol.2018.11.002] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
149 Thompson KD, Connor SJ, Walls DM, Gollins J, Stewart SK, Bewtra M, Baumblatt GL, Holubar SD, Greenup A, Sechi A, Girgis A, Rubin DT, Siegel CA. Patients with Ulcerative Colitis Are More Concerned About Complications of Their Disease than Side Effects of Medications: . Inflammatory Bowel Diseases 2016;22:940-7. [DOI: 10.1097/mib.0000000000000740] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
150 Britto S, Kellermayer R. Carbohydrate Monotony as Protection and Treatment for Inflammatory Bowel Disease. J Crohns Colitis 2019;13:942-8. [PMID: 30715243 DOI: 10.1093/ecco-jcc/jjz011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
151 Krishnareddy S, Swaminath A. When combination therapy isn’t working: Emerging therapies for the management of inflammatory bowel disease. World J Gastroenterol 2014; 20(5): 1139-1146 [PMID: 24574790 DOI: 10.3748/wjg.v20.i5.1139] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
152 Vos AC, Bakkal N, Minnee RC, Casparie MK, de Jong DJ, Dijkstra G, Stokkers P, van Bodegraven AA, Pierik M, van der Woude CJ, Oldenburg B, Hommes DW. Risk of malignant lymphoma in patients with inflammatory bowel diseases: A Dutch nationwide study: . Inflammatory Bowel Diseases 2011;17:1837-45. [DOI: 10.1002/ibd.21582] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 5.9] [Reference Citation Analysis]
153 Flynn AD, Azar JM, Chiorean MV. Spontaneous regression of colonic lymphoma following infliximab and azathioprine withdrawal in patients with Crohn's disease. Inflamm Bowel Dis 2013;19:E69-70. [PMID: 23399737 DOI: 10.1097/MIB.0b013e31827fec81] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
154 Taleban S. Challenges in the Diagnosis and Management of Inflammatory Bowel Disease in the Elderly. Curr Treat Options Gastro 2015;13:275-86. [DOI: 10.1007/s11938-015-0059-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
155 Rahier JF, Buche S, Peyrin-Biroulet L, Bouhnik Y, Duclos B, Louis E, Papay P, Allez M, Cosnes J, Cortot A. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8:1048-1055. [PMID: 20728573 DOI: 10.1016/j.cgh.2010.07.022] [Cited by in Crossref: 110] [Cited by in F6Publishing: 95] [Article Influence: 9.2] [Reference Citation Analysis]
156 Ye BD, Yang S, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim Y, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Guidelines for the Management of Crohn's Disease. Intest Res 2012;10:26. [DOI: 10.5217/ir.2012.10.1.26] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
157 Van Assche G, Lewis JD, Lichtenstein GR, Loftus EV, Ouyang Q, Panes J, Siegel CA, Sandborn WJ, Travis SP, Colombel JF. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 2011;106:1594-602; quiz 1593, 1603. [PMID: 21844919 DOI: 10.1038/ajg.2011.211] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
158 Civitelli F, Casciani E, Maccioni F, Oliva S, Al Ansari N, Bonocore V, Cucchiara S. Use of Imaging Techniques in Inflammatory Bowel Diseases That Minimize Radiation Exposure. Curr Gastroenterol Rep 2015;17. [DOI: 10.1007/s11894-015-0448-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
159 Cross RK. Which patients with inflammatory bowel disease should receive combination therapy? Expert Review of Gastroenterology & Hepatology 2015;9:715-7. [DOI: 10.1586/17474124.2015.1039989] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
160 Mitsialis V, Wu Y, Gewurz B, Bleday R, Doyle LA, Winter RW, Hamilton MJ. Raising the Barr: An Unexpected Lesion at Ileal-Cecal Resection. Dig Dis Sci 2019;64:353-7. [PMID: 30535887 DOI: 10.1007/s10620-018-5410-z] [Reference Citation Analysis]
161 Ardizzone S, Cassinotti A, Manes G, Porro GB. Immunomodulators for all patients with inflammatory bowel disease? Therap Adv Gastroenterol. 2010;3:31-42. [PMID: 21180588 DOI: 10.1177/1756283x09354136] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
162 Amin J, Huang B, Yoon J, Shih DQ. Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD. Inflamm Bowel Dis. 2015;21:445-452. [PMID: 25248004 DOI: 10.1097/mib.0000000000000197] [Cited by in Crossref: 47] [Cited by in F6Publishing: 27] [Article Influence: 6.7] [Reference Citation Analysis]
163 Ananthakrishnan AN, Sakuraba A, Barnes EL, Pekow J, Raffals L, Long MD, Sandler RS. The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. Aliment Pharmacol Ther 2017;46:162-8. [PMID: 28470787 DOI: 10.1111/apt.14125] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
164 Bewtra M, Newcomb CW, Wu Q, Chen L, Xie F, Roy JA, Aarons CB, Osterman MT, Forde KA, Curtis JR, Lewis JD. Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med 2015;163:262-70. [PMID: 26168366 DOI: 10.7326/M14-0960] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
165 Sands BE. The risks and benefits of early immunosuppression and biological therapy. Dig Dis. 2012;30 Suppl 3:100-106. [PMID: 23295699 DOI: 10.1159/000342731] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
166 Ben Musa R, Usha L, Hibbeln J, Mutlu EA. TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: A case report and literature review. World J Gastroenterol 2014; 20(19): 5912-5917 [PMID: 24914353 DOI: 10.3748/wjg.v20.i19.5912] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
167 Bell RD, Moriarty KJ. Synchronous colonic lymphoma and adenocarcinoma in a patient with Crohn's disease, treated with thiopurine therapy and a TNFα inhibitor: a challenge to Occam's razor. BMJ Case Rep 2016;2016:bcr2015212464. [PMID: 26791118 DOI: 10.1136/bcr-2015-212464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
168 Long MD, Hutfless S, Kappelman MD, Khalili H, Kaplan GG, Bernstein CN, Colombel JF, Gower-Rousseau C, Herrinton L, Velayos F, Loftus EV Jr, Nguyen GC, Ananthakrishnan AN, Sonnenberg A, Chan A, Sandler RS, Atreja A, Shah SA, Rothman KJ, Leleiko NS, Bright R, Boffetta P, Myers KD, Sands BE. Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm Bowel Dis 2014;20:398-415. [PMID: 24280882 DOI: 10.1097/01.MIB.0000435441.30107.8b] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
169 Sanguedolce F, Zanelli M, Zizzo M, Martino G, Rossi C, Parente P, Ascani S. Clinical, pathological and molecular features of plasmablastic lymphoma arising in the gastrointestinal tract: A review and reappraisal. Pathol Res Pract 2020;216:152973. [PMID: 32370987 DOI: 10.1016/j.prp.2020.152973] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
170 Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Langholff W, Londhe A, Sandborn WJ. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT™ Registry. Am J Gastroenterol. 2014;109:212-223. [PMID: 24394749 DOI: 10.1038/ajg.2013.441] [Cited by in Crossref: 125] [Cited by in F6Publishing: 107] [Article Influence: 15.6] [Reference Citation Analysis]
171 Anupindi SA, Grossman AB, Nimkin K, Mamula P, Gee MS. Imaging in the evaluation of the young patient with inflammatory bowel disease: what the gastroenterologist needs to know. J Pediatr Gastroenterol Nutr. 2014;59:429-439. [PMID: 24979661 DOI: 10.1097/mpg.0000000000000475] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 3.6] [Reference Citation Analysis]
172 Wong JJ, Sceats L, Dehghan M, Wren AA, Sellers ZM, Limketkai BN, Bensen R, Kin C, Park KT. Depression and Health Care Use in Patients With Inflammatory Bowel Disease. J Crohns Colitis 2019;13:19-26. [PMID: 30256923 DOI: 10.1093/ecco-jcc/jjy145] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
173 Kemp R, Dunn E, Schultz M. Immunomodulators in inflammatory bowel disease: an emerging role for biologic agents. BioDrugs 2013;27:585-90. [PMID: 23749336 DOI: 10.1007/s40259-013-0045-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
174 Chumanevich AA, Causey CP, Knuckley BA, Jones JE, Poudyal D, Chumanevich AP, Davis T, Matesic LE, Thompson PR, Hofseth LJ. Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor. Am J Physiol Gastrointest Liver Physiol 2011;300:G929-38. [PMID: 21415415 DOI: 10.1152/ajpgi.00435.2010] [Cited by in Crossref: 116] [Cited by in F6Publishing: 120] [Article Influence: 10.5] [Reference Citation Analysis]
175 Yarur AJ, Mandalia AB, Dauer RM, Czul F, Deshpande AR, Kerman DH, Abreu MT, Sussman DA. Predictive factors for clinically actionable computed tomography findings in inflammatory bowel disease patients seen in the emergency department with acute gastrointestinal symptoms. J Crohns Colitis. 2014;8:504-512. [PMID: 24275204 DOI: 10.1016/j.crohns.2013.11.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
176 Plaza R, Ponferrada A, Benito DM, Arevalo N, Foncillas MA, de Fuenmayor ML, Aldeguer M. Plasmablastic lymphoma associated to Crohn's disease and hepatitis C virus chronic infection. J Crohns Colitis 2011;5:628-32. [PMID: 22115386 DOI: 10.1016/j.crohns.2011.07.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
177 Siegel CA, Finlayson SR, Sands BE, Tosteson AN. Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. Clin Gastroenterol Hepatol 2012;10:46-51. [PMID: 21963958 DOI: 10.1016/j.cgh.2011.09.017] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
178 Nguyen DL, Flores S, Sassi K, Bechtold ML, Nguyen ET, Parekh NK. Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease. Ther Adv Chronic Dis 2015;6:147-54. [PMID: 25954499 DOI: 10.1177/2040622315579621] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
179 Wong U, Cross RK. Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease. Expert Opin Investig Drugs 2019;28:473-9. [PMID: 30884245 DOI: 10.1080/13543784.2019.1597053] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
180 Kim YJ, Kim JW, Lee CK, Park HJ, Shim JJ, Jang JY, Dong SH, Kim HJ, Kim BH, Chang YW. [Clinical outcome of treatment with infliximab in Crohn's disease: a single-center experience]. Korean J Gastroenterol 2013;61:270-8. [PMID: 23756669 DOI: 10.4166/kjg.2013.61.5.270] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
181 Torres J, Cravo M, Colombel JF. Anti-TNF Withdrawal in Inflammatory Bowel Disease. GE Port J Gastroenterol 2016;23:153-61. [PMID: 28868451 DOI: 10.1016/j.jpge.2015.11.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
182 Ghosh S, D'haens G, Feagan BG, Silverberg MS, Szigethy EM. What do changes in inflammatory bowel disease management mean for our patients? Journal of Crohn's and Colitis 2012;6:S243-9. [DOI: 10.1016/s1873-9946(12)60504-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
183 Reenaers C, Mary JY, Nachury M, Bouhnik Y, Laharie D, Allez M, Fumery M, Amiot A, Savoye G, Altwegg R, Devos M, Malamut G, Bourreille A, Flourie B, Marteau P, Vuitton L, Coffin B, Viennot S, Lambert J, Colombel JF, Louis E; Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif. Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission. Clin Gastroenterol Hepatol. 2018;16:234-243.e2. [PMID: 28993262 DOI: 10.1016/j.cgh.2017.09.061] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 8.2] [Reference Citation Analysis]
184 Foppoli M, Ferreri AJ. Gamma-delta t-cell lymphomas. Eur J Haematol 2015;94:206-18. [PMID: 25154298 DOI: 10.1111/ejh.12439] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
185 Targownik LE, Bernstein CN. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol. 2013;108:1835-1842, quiz 1843. [PMID: 24042192 DOI: 10.1038/ajg.2013.294] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 7.9] [Reference Citation Analysis]
186 Kamm MA, Ng SC, De Cruz P, Allen P, Hanauer SB. Practical application of anti-TNF therapy for luminal Crohn’s disease. Inflamm Bowel Dis. 2011;17:2366-2391. [PMID: 21337669 DOI: 10.1002/ibd.21655] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
187 Denson LA, Long MD, McGovern DP, Kugathasan S, Wu GD, Young VB, Pizarro TT, de Zoeten EF, Stappenbeck TS, Plevy SE. Challenges in IBD research: update on progress and prioritization of the CCFA’s research agenda. Inflamm Bowel Dis. 2013;19:677-682. [PMID: 23448796 DOI: 10.1097/mib.0b013e31828134b3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
188 Dulai PS, Siegel CA. The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. Gastroenterol Clin North Am 2014;43:525-41. [PMID: 25110257 DOI: 10.1016/j.gtc.2014.05.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
189 Van Hauwaert V, Meers S, Verhoef G, Tousseyn T, Sagaert X, Vermeire S, Rutgeerts P, Van Assche G. Rectal non-Hodgkin‘s lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitis. J Crohns Colitis. 2010;4:683-686. [PMID: 21122582 DOI: 10.1016/j.crohns.2010.06.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
190 Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:167-182. [PMID: 20227030 DOI: 10.1016/j.bpg.2010.01.002] [Cited by in Crossref: 114] [Cited by in F6Publishing: 103] [Article Influence: 9.5] [Reference Citation Analysis]
191 Lin SC, Goldowsky A, Papamichael K, Cheifetz AS. The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy. Inflamm Bowel Dis 2019;25:998-1005. [PMID: 30590558 DOI: 10.1093/ibd/izy376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
192 Legué C, Brochard C, Bessi G, Wallenhorst T, Dewitte M, Siproudhis L, Bouguen G. Outcomes of Perianal Fistulising Crohn’s Disease Following Anti-TNFα Treatment Discontinuation. Inflammatory Bowel Diseases 2018;24:1107-13. [DOI: 10.1093/ibd/izy008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
193 Dignass A, Akbar A, Baumgart DC, Bommelaer G, Bouguen G, Cadiot G, Gillessen A, Grimaud JC, Hart A, Hoque S, Makins R, Michiels C, Moreau J, Premchand P, Ramlow W, Schanz S, Subramanian S, von Tirpitz C, Bonaz B. Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis. Scand J Gastroenterol. 2018;53:442-448. [PMID: 29513111 DOI: 10.1080/00365521.2018.1447598] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
194 Zhang T, Wang Z, Fan R, Zhang M, Lin Y, Hong L, Zhou X, Hu S, Cheng M, Zhong J. The Efficacy of Infliximab Monotherapy versus Infliximab-Azathioprine Sequential Treatment in Crohn's Disease: Experience from a Tertiary Medical Center in China. Biomed Res Int 2016;2016:8648307. [PMID: 27896276 DOI: 10.1155/2016/8648307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
195 Côté-Daigneault J, Bernard EJ. Hepatosplenic lymphoma presenting initially as hemophagocytic syndrome in a 21-year-old man with Crohn's disease: a case report and literature review. Can J Gastroenterol 2011;25:417-8. [PMID: 21912765 DOI: 10.1155/2011/148927] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
196 Nuti F, Fiorino G, Danese S. Adalimumab for the treatment of pediatric Crohn’s disease. Expert Review of Clinical Immunology 2015;11:963-72. [DOI: 10.1586/1744666x.2015.1072048] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
197 Aksu K, Cagirgan S, Ozsan N, Keser G, Sahin F. Non-Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis. Rheumatol Int 2011;31:1645-7. [PMID: 20013270 DOI: 10.1007/s00296-009-1265-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
198 Boyapati RK, Torres J, Palmela C, Parker CE, Silverberg OM, Upadhyaya SD, Nguyen TM, Colombel JF. Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease. Cochrane Database Syst Rev 2018;5:CD012540. [PMID: 29756637 DOI: 10.1002/14651858.CD012540.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
199 Biancone L, Petruzziello C, Orlando A, Kohn A, Ardizzone S, Daperno M, Angelucci E, Castiglione F, D'Incà R, Zorzi F. Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis. 2011;17:758-766. [PMID: 20684009 DOI: 10.1002/ibd.21416] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
200 Chang J, Leong RW. Occupational health and safety of anti-tumour necrosis factor alpha monoclonal antibodies with casual exposure. Expert Opinion on Biological Therapy 2013;14:27-36. [DOI: 10.1517/14712598.2014.853738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
201 Pierre N, Baiwir D, Huynh-Thu VA, Mazzucchelli G, Smargiasso N, De Pauw E, Bouhnik Y, Laharie D, Colombel JF, Meuwis MA, Louis E; GETAID (Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif). Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn's patients: a proteomics-based study.Gut. 2020;. [PMID: 33106355 DOI: 10.1136/gutjnl-2020-322100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
202 Sansone S, Guarino M, Castiglione F, Rispo A, Auriemma F, Loperto I, Rea M, Caporaso N, Morisco F. Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(13): 3516-3524 [PMID: 24707134 DOI: 10.3748/wjg.v20.i13.3516] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
203 Lee JC, Lyons PA, McKinney EF, Sowerby JM, Carr EJ, Bredin F, Rickman HM, Ratlamwala H, Hatton A, Rayner TF, Parkes M, Smith KG. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest 2011;121:4170-9. [PMID: 21946256 DOI: 10.1172/JCI59255] [Cited by in Crossref: 179] [Cited by in F6Publishing: 91] [Article Influence: 16.3] [Reference Citation Analysis]
204 Ananthakrishnan AN. Personalizing therapy for inflammatory bowel diseases. Expert Rev Gastroenterol Hepatol 2013;7:549-58. [PMID: 23985004 DOI: 10.1586/17474124.2013.824693] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
205 Rojas-Feria M, Eslam M, Castro-Fernández M, Guerrero P, Larraona-Moreno JL, Romero-Gómez M. Cutaneous lymphoma in a patient with ulcerative colitis after immunosuppressive therapy. J Crohns Colitis 2011;5:608-11. [PMID: 22115382 DOI: 10.1016/j.crohns.2011.04.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
206 Kedia S, Limdi JK, Ahuja V. Management of inflammatory bowel disease in older persons: evolving paradigms. Intest Res 2018;16:194-208. [PMID: 29743832 DOI: 10.5217/ir.2018.16.2.194] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
207 Nimmons D, Limdi JK. Elderly patients and inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016; 7(1): 51-65 [PMID: 26855812 DOI: 10.4292/wjgpt.v7.i1.51] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
208 Makanyanga JC, Taylor SA. Current and future role of MR enterography in the management of Crohn disease. AJR Am J Roentgenol. 2013;201:56-64. [PMID: 23789658 DOI: 10.2214/ajr.12.10406] [Cited by in Crossref: 29] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
209 Garg SK, Loftus EV. Risk of cancer in inflammatory bowel disease: going up, going down, or still the same? Current Opinion in Gastroenterology 2016;32:274-81. [DOI: 10.1097/mog.0000000000000286] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
210 Morisco F, Castiglione F, Rispo A, Stroffolini T, Vitale R, Sansone S, Granata R, Orlando A, Marmo R, Riegler G. Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Dig Liver Dis. 2011;43 Suppl 1:S40-S48. [PMID: 21195371 DOI: 10.1016/s1590-8658(10)60691-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
211 Golder S, Loke YK. The performance of adverse effects search filters in MEDLINE and EMBASE. Health Info Libr J 2012;29:141-51. [PMID: 22630362 DOI: 10.1111/j.1471-1842.2012.00980.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
212 de Jong ME, Smits LJT, van Ruijven B, den Broeder N, Russel MGVM, Römkens TEH, West RL, Jansen JM, Hoentjen F. Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients. Journal of Crohn's and Colitis 2020;14:888-95. [DOI: 10.1093/ecco-jcc/jjaa012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
213 Butler SL, Valdez H, Westby M, Perros M, June CH, Jacobson JM, Levy Y, Cooper DA, Douek D, Lederman MM, Tebas P. Disease-modifying therapeutic concepts for HIV in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2011;58:297-303. [PMID: 21792065 DOI: 10.1097/QAI.0b013e31822ccfcc] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
214 Dohan A, Faraoun S, Barral M, Guerrache Y, Boudiaf M, Dray X, Hoeffel C, Allez M, Farges O, Beaugerie L, Aparicio T, Marteau P, Fishman E, Lucidarme O, Eveno C, Pocard M, Dautry R, Soyer P. Extra-intestinal malignancies in inflammatory bowel diseases: An update with emphasis on MDCT and MR imaging features. Diagnostic and Interventional Imaging 2015;96:871-83. [DOI: 10.1016/j.diii.2015.02.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
215 Ye BD, Yang SK, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim YH, Lee H. [Guidelines for the management of Crohn’s disease]. Korean J Gastroenterol. 2012;59:141-179. [PMID: 22387837 DOI: 10.4166/kjg.2012.59.2.141] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
216 Chowers Y. Taking Crohn's disease personally. Rambam Maimonides Med J 2013;4:e0011. [PMID: 23908861 DOI: 10.5041/RMMJ.10111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
217 Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12:1443-1451; quiz e88-9. [PMID: 24462626 DOI: 10.1016/j.cgh.2014.01.021] [Cited by in Crossref: 94] [Cited by in F6Publishing: 79] [Article Influence: 11.8] [Reference Citation Analysis]
218 Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011;106:2146-53. [PMID: 22031357 DOI: 10.1038/ajg.2011.283] [Cited by in Crossref: 132] [Cited by in F6Publishing: 118] [Article Influence: 12.0] [Reference Citation Analysis]
219 Nasiri S, Kuenzig ME, Benchimol EI. Long-term outcomes of pediatric inflammatory bowel disease. Seminars in Pediatric Surgery 2017;26:398-404. [DOI: 10.1053/j.sempedsurg.2017.10.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
220 Ha C, Dassopoulos T. Thiopurine therapy in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2010;4:575-588. [PMID: 20932143 DOI: 10.1586/egh.10.59] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
221 Chu BK, Scott FI, Bewtra M. Optimal Placement of Colectomy in the Treatment of Ulcerative Colitis: a Markov Model Analysis. J Gastrointest Surg 2021. [PMID: 34725785 DOI: 10.1007/s11605-021-05180-1] [Reference Citation Analysis]
222 Sandberg K, Yarger E, Saeed S. Updates in diagnosis and management of inflammatory bowel disease.Curr Probl Pediatr Adolesc Health Care. 2020;50:100785. [PMID: 32402535 DOI: 10.1016/j.cppeds.2020.100785] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
223 Gouldthorpe O, Catto-Smith AG, Alex G. Biologics in paediatric Crohn's disease. Gastroenterol Res Pract 2011;2011:287574. [PMID: 22144993 DOI: 10.1155/2011/287574] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
224 Sultan K, Inamdar S, Hirten R. The Uncertain Role of Immunomodulator Maintenance After Cessation of Anti-Tumor Necrosis Factor α Therapy. Clin Gastroenterol Hepatol 2015;13:1551-2. [PMID: 25599656 DOI: 10.1016/j.cgh.2015.01.006] [Reference Citation Analysis]
225 Fernandez Salazar L, Rojo S, De Lejarazu RO, Castro E, Higuera E, González JM. No increase in Epstein-Barr virus viral load in a group of 30 asymptomatic patients with Crohn’s disease. Am J Gastroenterol. 2013;108:1933-1935. [PMID: 24300873 DOI: 10.1038/ajg.2013.250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
226 Sokol H, Beaugerie L, Maynadié M, Laharie D, Dupas JL, Flourié B, Lerebours E, Peyrin-Biroulet L, Allez M, Simon T. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2063-2071. [PMID: 22271569 DOI: 10.1002/ibd.22889] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 6.6] [Reference Citation Analysis]
227 Nussinson E, Shibli F, Shahbari A, Rock W, Elias M, Elmalah I. Primary effusion lymphoma-like lymphoma in a patient with inflammatory bowel disease. World J Gastroenterol 2014; 20(3): 857-862 [PMID: 24574759 DOI: 10.3748/wjg.v20.i3.857] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
228 Taborelli M, Sozzi M, Del Zotto S, Toffolutti F, Montico M, Zanier L, Serraino D. Risk of intestinal and extra-intestinal cancers in patients with inflammatory bowel diseases: A population-based cohort study in northeastern Italy. PLoS One 2020;15:e0235142. [PMID: 32574216 DOI: 10.1371/journal.pone.0235142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
229 van Asseldonk DP, Sanderson J, de Boer NK, Sparrow MP, Lémann M, Ansari A, Almer SH, Florin TH, Gearry RB, Mulder CJ. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease--proceedings of the first Thiopurine Task Force meeting. Dig Liver Dis. 2011;43:270-276. [PMID: 20934926 DOI: 10.1016/j.dld.2010.09.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
230 Xu S, Chen H, Zu X, Hao X, Feng R, Zhang S, Chen B, Zeng Z, Chen M, Ye Z, He Y. Epstein-Barr virus infection in ulcerative colitis: a clinicopathologic study from a Chinese area. Therap Adv Gastroenterol 2020;13:1756284820930124. [PMID: 32913442 DOI: 10.1177/1756284820930124] [Reference Citation Analysis]
231 Rubin DT, Huo D, Kinnucan JA, Sedrak MS, McCullom NE, Bunnag AP, Raun-Royer EP, Cohen RD, Hanauer SB, Hart J. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013;11:1601-1608.e1-e4. [PMID: 23872237 DOI: 10.1016/j.cgh.2013.06.023] [Cited by in Crossref: 179] [Cited by in F6Publishing: 157] [Article Influence: 19.9] [Reference Citation Analysis]
232 Peake ST, Bernardo D, Mann ER, Al-Hassi HO, Knight SC, Hart AL. Mechanisms of action of anti-tumor necrosis factor α agents in Crohn's disease. Inflamm Bowel Dis 2013;19:1546-55. [PMID: 23594837 DOI: 10.1097/MIB.0b013e318281333b] [Cited by in Crossref: 37] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
233 Papamichael K, Mantzaris GJ, Peyrin-Biroulet L. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease. Expert Opin Drug Saf 2016;15:493-501. [PMID: 26799429 DOI: 10.1517/14740338.2016.1145653] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
234 Mosli MH, Sandborn WJ, Kim RB, Khanna R, Al-Judaibi B, Feagan BG. Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol 2014;109:994-1004. [PMID: 24842338 DOI: 10.1038/ajg.2014.110] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
235 de Ridder L, Turner D, Wilson DC, Koletzko S, Martin-de-Carpi J, Fagerberg UL, Spray C, Sladek M, Shaoul R, Roma-Giannikou E, Bronsky J, Serban DE, Cucchiara S, Veres G, Ruemmele FM, Hojsak I, Kolho KL, Davies IH, Aloi M, Lionetti P, Veereman-Wauters G, Braegger CP, Trindade E, Wewer AV, Hauer A, Levine A; Porto IBD Working Group of ESPGHAN. Malignancy and mortality in pediatric patients with inflammatory bowel disease: a multinational study from the porto pediatric IBD group. Inflamm Bowel Dis 2014;20:291-300. [PMID: 24374875 DOI: 10.1097/01.MIB.0000439066.69340.3c] [Cited by in Crossref: 45] [Cited by in F6Publishing: 10] [Article Influence: 6.4] [Reference Citation Analysis]
236 O’neill I, Scully C. Biologics in oral medicine: oral Crohn’s disease and orofacial granulomatosis: Biologics: oral Crohn’s and OFG. Oral Diseases 2012;18:633-8. [DOI: 10.1111/j.1601-0825.2012.01918.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
237 Nielsen OH, Bjerrum JT, Seidelin JB, Nyberg C, Ainsworth M. Biological treatment of Crohn’s disease. Dig Dis. 2012;30 Suppl 3:121-133. [PMID: 23295703 DOI: 10.1159/000342738] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
238 Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, El-hussuna A, Ellul P, Frei-lanter C, Furfaro F, Gingert C, Gionchetti P, Gomollon F, González-lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Lytras T, Maaser C, Magro F, Kenneth Marshall J, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Spinelli A, Stassen L, Uzzan M, Vavricka S, Verstockt B, Warusavitarne J, Zmora O, Fiorino G. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis 2020;14:4-22. [DOI: 10.1093/ecco-jcc/jjz180] [Cited by in Crossref: 184] [Cited by in F6Publishing: 153] [Article Influence: 61.3] [Reference Citation Analysis]
239 Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390-399.e1. [PMID: 22584081 DOI: 10.1053/j.gastro.2012.05.004] [Cited by in Crossref: 284] [Cited by in F6Publishing: 248] [Article Influence: 28.4] [Reference Citation Analysis]
240 Nielsen OH, Coskun M, Steenholdt C, Rogler G. The role and advances of immunomodulator therapy for inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2014;9:177-89. [DOI: 10.1586/17474124.2014.945914] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
241 Rosenberg LN, Peppercorn MA. Efficacy and safety of drugs for ulcerative colitis. Expert Opinion on Drug Safety 2010;9:573-92. [DOI: 10.1517/14740331003639412] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
242 Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. JAMA 2017;318:1679-86. [PMID: 29114832 DOI: 10.1001/jama.2017.16071] [Cited by in Crossref: 229] [Cited by in F6Publishing: 193] [Article Influence: 45.8] [Reference Citation Analysis]
243 Chaparala A, Poudyal D, Tashkandi H, Witalison EE, Chumanevich AA, Hofseth JL, Nguyen I, Hardy O, Pittman DL, Wyatt MD, Windust A, Murphy EA, Nagarkatti M, Nagarkatti P, Hofseth LJ. Panaxynol, a bioactive component of American ginseng, targets macrophages and suppresses colitis in mice. Oncotarget 2020;11:2026-36. [PMID: 32547701 DOI: 10.18632/oncotarget.27592] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
244 Parian A, Lazarev M. Who and how to screen for cancer in at-risk inflammatory bowel disease patients. Expert Rev Gastroenterol Hepatol 2015;9:731-46. [PMID: 25592672 DOI: 10.1586/17474124.2015.1003208] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
245 Cipriano LE, Levesque BG, Zaric GS, Loftus EV Jr, Sandborn WJ. Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease. Inflamm Bowel Dis 2012;18:1240-8. [PMID: 21928375 DOI: 10.1002/ibd.21862] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
246 Maung SW, Desmond R, Mchugh J, Ryan B, Neary P, Jeffers M, Enright H. A coincidence or a rare occurrence? A case of plasmablastic lymphoma of the small intestines following infliximab treatment for Crohn’s disease. Ann Hematol 2016;95:149-50. [DOI: 10.1007/s00277-015-2497-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
247 Siegel CA, Thompson KD, Walls D, Gollins J, Buisson A, Olympie A, Beaugerie L, Colombel J, Louis E. Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohn’s Disease. Clinical Gastroenterology and Hepatology 2021;19:403-5. [DOI: 10.1016/j.cgh.2019.11.062] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
248 Biancone L, Zuzzi S, Ranieri M, Petruzziello C, Calabrese E, Onali S, Ascolani M, Zorzi F, Condino G, Iacobelli S. Fistulizing pattern in Crohn’s disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study. J Crohns Colitis. 2012;6:578-587. [PMID: 22398047 DOI: 10.1016/j.crohns.2011.11.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
249 Herndon K, Dewitt A, Gillion A, Pattanaik D. Infusion-related angioedema associated with infliximab-abda: Case report. American Journal of Health-System Pharmacy 2021;78:108-12. [DOI: 10.1093/ajhp/zxaa321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
250 Ballester Ferré MP, Boscá-Watts MM, Mínguez Pérez M. Crohn's disease. Med Clin (Barc) 2018;151:26-33. [PMID: 29246562 DOI: 10.1016/j.medcli.2017.10.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
251 Yang C, Huang J, Huang X, Huang S, Cheng J, Liao W, Chen X, Wang X, Dai S. Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-tumour Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis. J Crohns Colitis 2018;12:1042-52. [PMID: 29762681 DOI: 10.1093/ecco-jcc/jjy065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
252 Muller M, Broséus J, Feugier P, Thieblemont C, Beaugerie L, Danese S, Arnone D, Ndiaye NC, Kokten T, Houlgatte R, Peyrin-Biroulet L. Characteristics of Lymphoma in Patients with Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis 2021;15:827-39. [PMID: 32949235 DOI: 10.1093/ecco-jcc/jjaa193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
253 Sultan K, Korelitz BI, Present D, Katz S, Sunday S, Shapira I. Prognosis of lymphoma in patients following treatment with 6-mercaptopurine/azathioprine for inflammatory bowel disease. Inflamm Bowel Dis 2012;18:1855-8. [PMID: 22241664 DOI: 10.1002/ibd.22866] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
254 Subramaniam K, D'Rozario J, Pavli P. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review. J Gastroenterol Hepatol. 2013;28:24-30. [PMID: 23094824 DOI: 10.1111/jgh.12015] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 5.9] [Reference Citation Analysis]
255 Hashash JG, Fadel CGA, Rimmani HH, Sharara AI. Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn's disease and ulcerative colitis. Ann Gastroenterol 2021;34:612-24. [PMID: 34475731 DOI: 10.20524/aog.2021.0645] [Reference Citation Analysis]
256 Gordon JP, McEwan PC, Maguire A, Sugrue DM, Puelles J. Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol 2015;27:804-12. [PMID: 25933126 DOI: 10.1097/MEG.0000000000000378] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
257 Ampuero J, Rojas-Feria M, Castro-Fernández M, Millán-Lorenzo M, Guerrero-Jiménez P, Romero-Gómez M. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's Disease in clinical practice. J Gastroenterol Hepatol. 2015;Epub ahead of print. [PMID: 26173493 DOI: 10.1111/jgh.13039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
258 Setoyama H, Ido A, Numata M, Moriuchi A, Yamaji N, Tamai T, Funakawa K, Fujita H, Sakiyama T, Uto H, Oketani M, Tsubouchi H. Repeated enemas with hepatocyte growth factor selectively stimulate epithelial cell proliferation of injured mucosa in rats with experimental colitis. Life Sci 2011;89:269-75. [PMID: 21763320 DOI: 10.1016/j.lfs.2011.06.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
259 Louis E, Mary J, Vernier–massouille G, Grimaud J, Bouhnik Y, Laharie D, Dupas J, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud G, Piver E, Colombel J, Lemann M. Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped. Gastroenterology 2012;142:63-70.e5. [DOI: 10.1053/j.gastro.2011.09.034] [Cited by in Crossref: 396] [Cited by in F6Publishing: 351] [Article Influence: 39.6] [Reference Citation Analysis]
260 Luria L, Nguyen J, Zhou J, Jaglal M, Sokol L, Messina JL, Coppola D, Zhang L. Manifestations of gastrointestinal plasmablastic lymphoma: A case series with literature review. World J Gastroenterol 2014; 20(33): 11894-11903 [PMID: 25206297 DOI: 10.3748/wjg.v20.i33.11894] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
261 Siegel CA. Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy. Inflamm Bowel Dis 2010;16:2168-72. [PMID: 20848508 DOI: 10.1002/ibd.21305] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
262 Arnott I, Rogler G, Halfvarson J. The Management of Inflammatory Bowel Disease in Elderly: Current Evidence and Future Perspectives. Inflamm Intest Dis 2018;2:189-99. [PMID: 30221146 DOI: 10.1159/000490053] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
263 Loftus EV, Colombel J, Schreiber S, Randall CW, Regueiro M, Ali T, Arendt C, Coarse J, Spearman M, Kosutic G. Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials. Clinical Gastroenterology and Hepatology 2016;14:1753-62. [DOI: 10.1016/j.cgh.2016.07.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
264 Butter M, Weiler S, Biedermann L, Scharl M, Rogler G, Bischoff-ferrari HA, Misselwitz B. Clinical manifestations, pathophysiology, treatment and outcome of inflammatory bowel diseases in older people. Maturitas 2018;110:71-8. [DOI: 10.1016/j.maturitas.2018.01.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
265 Papamichael K, Vande Casteele N, Gils A, Tops S, Hauenstein S, Singh S, Princen F, Van Assche G, Rutgeerts P, Vermeire S, Ferrante M. Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission. Clin Gastroenterol Hepatol. 2015;13:1103-1110. [PMID: 25478919 DOI: 10.1016/j.cgh.2014.11.026] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 7.9] [Reference Citation Analysis]
266 Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, Dierickx D, Dummer R, Fiorino G, Gornet JM, Higgins P, Katsanos KH, Nissen L, Pellino G, Rogler G, Scaldaferri F, Szymanska E, Eliakim R; ECCO. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2015;9:945-965. [PMID: 26294789 DOI: 10.1093/ecco-jcc/jjv141] [Cited by in Crossref: 189] [Cited by in F6Publishing: 170] [Article Influence: 27.0] [Reference Citation Analysis]
267 Segal JP, Askari A, Clark SK, Hart AL, Faiz OD. The Incidence and Prevalence of Human Papilloma Virus-associated Cancers in IBD. Inflamm Bowel Dis 2021;27:34-9. [PMID: 32080713 DOI: 10.1093/ibd/izaa035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
268 Corte C, Saxena P, Tattersall S, Selinger C, Leong RW. When to use biological agents in inflammatory bowel disease. J Gastroenterol Hepatol 2012;27:1141-9. [PMID: 22188169 DOI: 10.1111/j.1440-1746.2011.07056.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
269 Melmed GY, Targan SR. Future biologic targets for IBD: potentials and pitfalls. Nat Rev Gastroenterol Hepatol. 2010;7:110-117. [PMID: 20134493 DOI: 10.1038/nrgastro.2009.218] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 4.8] [Reference Citation Analysis]
270 Day AS, Gulati AS, Patel N, Boyle B, Park KT, Saeed SA. The Role of Combination Therapy in Pediatric Inflammatory Bowel Disease: A Clinical Report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;66:361-8. [PMID: 29210919 DOI: 10.1097/MPG.0000000000001850] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
271 Taleban S, Elquza E, Gower-rousseau C, Peyrin-biroulet L. Cancer and inflammatory bowel disease in the elderly. Digestive and Liver Disease 2016;48:1105-11. [DOI: 10.1016/j.dld.2016.05.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
272 Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106:685-698. [PMID: 21427713 DOI: 10.1038/ajg.2011.103] [Cited by in Crossref: 202] [Cited by in F6Publishing: 198] [Article Influence: 18.4] [Reference Citation Analysis]
273 Seminerio JL, Loftus EV, Colombel JF, Thapa P, Sandborn WJ. Infliximab for Crohn’s disease: the first 500 patients followed up through 2009. Dig Dis Sci. 2013;58:797-806. [PMID: 23053885 DOI: 10.1007/s10620-012-2405-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
274 Ward MG, Irving PM, Sparrow MP. How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease? World J Gastroenterol 2015; 21(40): 11331-11342 [PMID: 26525434 DOI: 10.3748/wjg.v21.i40.11331] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
275 Swoger JM, Regueiro M. Stopping, Continuing, or Restarting Immunomodulators and Biologics When an Infection or Malignancy Develops: . Inflammatory Bowel Diseases 2014;20:926-35. [DOI: 10.1097/mib.0000000000000002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
276 Kollepara SS, Chisti MM, Shatavi SV, Jaiyesimi IA. Peripheral T-cell lymphoma in a patient with Crohn's disease. BMJ Case Rep 2013;2013:bcr2013200606. [PMID: 24114599 DOI: 10.1136/bcr-2013-200606] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
277 Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10:585-595. [PMID: 23835489 DOI: 10.1038/nrgastro.2013.117] [Cited by in Crossref: 124] [Cited by in F6Publishing: 115] [Article Influence: 13.8] [Reference Citation Analysis]
278 Kim JH, Kim JW. Effect of Immunomodulators and Biologic Agents on Malignancy in Patients with Inflammatory Bowel Disease. Korean J Gastroenterol 2017;70:162. [DOI: 10.4166/kjg.2017.70.4.162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
279 Kelsen JR, Sullivan KE. Inflammatory Bowel Disease in Primary Immunodeficiencies. Curr Allergy Asthma Rep 2017;17:57. [PMID: 28755025 DOI: 10.1007/s11882-017-0724-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
280 Ioannidis JP, Zhou Y, Chang CQ, Schully SD, Khoury MJ, Freedman AN. Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses. Ann Oncol 2014;25:16-23. [PMID: 24310915 DOI: 10.1093/annonc/mdt372] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
281 Coskun M, Steenholdt C, de Boer NK, Nielsen OH. Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease. Clin Pharmacokinet. 2016;55:257-274. [PMID: 26255287 DOI: 10.1007/s40262-015-0316-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
282 Dulai PS, Siegel CA, Peyrin-Biroulet L. Anti-tumor necrosis factor-α monotherapy versus combination therapy with an immunomodulator in IBD. Gastroenterol Clin North Am 2014;43:441-56. [PMID: 25110252 DOI: 10.1016/j.gtc.2014.05.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
283 Volonaki E, Mutalib M, Kiparissi F, Shah N, Lindley KJ, Elawad M. Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis: . European Journal of Gastroenterology & Hepatology 2015;27:1425-8. [DOI: 10.1097/meg.0000000000000470] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 1.9] [Reference Citation Analysis]
284 Ruemmele FM, Rosh J, Faubion WA, Dubinsky MC, Turner D, Lazar A, Eichner S, Maa JF, Alperovich G, Robinson AM, Hyams JS. Efficacy of Adalimumab for Treatment of Perianal Fistula in Children with Moderately to Severely Active Crohn's Disease: Results from IMAgINE 1 and IMAgINE 2. J Crohns Colitis. 2018;12:1249-1254. [PMID: 29939254 DOI: 10.1093/ecco-jcc/jjy087] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
285 Netz U, Carter JV, Eichenberger MR, Dryden GW, Pan J, Rai SN, Galandiuk S. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease. World J Gastroenterol 2017; 23(27): 4958-4967 [PMID: 28785150 DOI: 10.3748/wjg.v23.i27.4958] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
286 Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T; HAYABUSA Study Group. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol 2021;6:429-37. [PMID: 33887262 DOI: 10.1016/S2468-1253(21)00062-5] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
287 Ha C, Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand? Curr Gastroenterol Rep. 2010;12:471-478. [PMID: 20886319 DOI: 10.1007/s11894-010-0146-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
288 Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1598-1619. [PMID: 20198712 DOI: 10.1002/ibd.21219] [Cited by in Crossref: 133] [Cited by in F6Publishing: 115] [Article Influence: 11.1] [Reference Citation Analysis]
289 Eder P, Niezgódka A, Krela-Kaźmierczak I, Stawczyk-Eder K, Banasik E, Dobrowolska A. Dietary Support in Elderly Patients with Inflammatory Bowel Disease. Nutrients 2019;11:E1421. [PMID: 31238597 DOI: 10.3390/nu11061421] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
290 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
291 Kaplan GG, Ng SC. Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China. Lancet Gastroenterol Hepatol. 2016;1:307-316. [PMID: 28404201 DOI: 10.1016/s2468-1253(16)30077-2] [Cited by in Crossref: 67] [Cited by in F6Publishing: 30] [Article Influence: 11.2] [Reference Citation Analysis]
292 Kim D, Taleban S. A Comprehensive Review of the Diagnosis and Pharmacological Management of Crohn's Disease in the Elderly Population. Drugs Aging 2019;36:607-24. [PMID: 31055789 DOI: 10.1007/s40266-019-00672-x] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
293 Cheifetz AS. Management of active Crohn disease. JAMA 2013;309:2150-8. [PMID: 23695484 DOI: 10.1001/jama.2013.4466] [Cited by in Crossref: 72] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
294 Shah ED, Coburn ES, Nayyar A, Lee KJ, Koliani-Pace JL, Siegel CA. Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System. Aliment Pharmacol Ther 2020;51:527-33. [PMID: 31990422 DOI: 10.1111/apt.15637] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
295 Trikudanathan G, Venkatesh PG, Navaneethan U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs. 2012;72:2333-2349. [PMID: 23181971 DOI: 10.165/11638120-000000000-00000] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
296 Leung G, Papademetriou M, Chang S, Arena F, Katz S. Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy. Curr Treat Options Gastro 2016;14:507-34. [DOI: 10.1007/s11938-016-0109-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
297 Shi HY, Ng SC. The state of the art on treatment of Crohn's disease. J Gastroenterol. 2018;53:989-998. [PMID: 29980848 DOI: 10.1007/s00535-018-1479-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
298 Levy LC, Siegel CA. Commentary: diagnostic medical radiation exposure in inflammatory bowel disease. Aliment Pharmacol Ther 2012;35:959-60. [DOI: 10.1111/j.1365-2036.2012.05035.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
299 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
300 Bewtra M, Lewis JD. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:621-31. [PMID: 20594135 DOI: 10.1586/eci.10.36] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
301 Smith MA, Irving PM, Marinaki AM, Sanderson JD. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther. 2010;32:119-130. [PMID: 20412066 DOI: 10.1111/j.1365-2036.2010.04330.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 5.4] [Reference Citation Analysis]
302 Chudy-Onwugaje KO, Christian KE, Farraye FA, Cross RK. A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD. Inflamm Bowel Dis 2019;25:820-30. [PMID: 30445504 DOI: 10.1093/ibd/izy327] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 16.0] [Reference Citation Analysis]
303 Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opinion on Biological Therapy 2013;14:75-101. [DOI: 10.1517/14712598.2014.858695] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 9.4] [Reference Citation Analysis]
304 Ha C, Mathur J, Kornbluth A. Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2015;9:497-505. [PMID: 25600263 DOI: 10.1586/17474124.2015.983079] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
305 Dignass A, Van Assche G, Lindsay J, Lémann M, Söderholm J, Colombel J, Danese S, D'hoore A, Gassull M, Gomollón F, Hommes D, Michetti P, O'morain C, Öresland T, Windsor A, Stange E, Travis S. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. Journal of Crohn's and Colitis 2010;4:28-62. [DOI: 10.1016/j.crohns.2009.12.002] [Cited by in Crossref: 981] [Cited by in F6Publishing: 886] [Article Influence: 81.8] [Reference Citation Analysis]
306 de Bie CI, Escher JC, de Ridder L. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:985-1002. [PMID: 21936033 DOI: 10.1002/ibd.21871] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
307 Bewtra M, Kilambi V, Fairchild AO, Siegel CA, Lewis JD, Johnson FR. Patient preferences for surgical versus medical therapy for ulcerative colitis. Inflamm Bowel Dis 2014;20:103-14. [PMID: 24280881 DOI: 10.1097/01.MIB.0000437498.14804.50] [Cited by in Crossref: 54] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
308 Cozijnsen MA, Samsom JN, de Ridder L. Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn's Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability. Paediatr Drugs 2018;20:19-28. [PMID: 29079905 DOI: 10.1007/s40272-017-0266-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
309 Akobeng AA, Sandborn WJ, Bickston SJ, Chande N, Shackelton LM, Nelson S, Feagan BG. Tumor Necrosis Factor-Alpha Antagonists Twenty Years Later: What Do Cochrane Reviews Tell Us? Inflammatory Bowel Diseases 2014;20:2132-41. [DOI: 10.1097/mib.0000000000000218] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
310 Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn’s disease: one size does not fit all. Clin Gastroenterol Hepatol. 2010;8:655-659. [PMID: 20451665 DOI: 10.1016/j.cgh.2010.04.023] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
311 Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, Elmunzer BJ, Saini SD, Vijan S, Waljee AK. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39:660-671. [PMID: 24506179 DOI: 10.1111/apt.12644] [Cited by in Crossref: 104] [Cited by in F6Publishing: 95] [Article Influence: 13.0] [Reference Citation Analysis]
312 Mason M, Siegel CA. Do inflammatory bowel disease therapies cause cancer? Inflamm Bowel Dis. 2013;19:1306-1321. [PMID: 23470503 DOI: 10.1097/mib.0b013e3182807618] [Cited by in Crossref: 38] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
313 Li L, Guo J, Wang Y, Xiong X, Tao H, Li J, Jia Y, Hu H, Zhang J. A Broad-Spectrum ROS-Eliminating Material for Prevention of Inflammation and Drug-Induced Organ Toxicity. Adv Sci (Weinh) 2018;5:1800781. [PMID: 30356945 DOI: 10.1002/advs.201800781] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
314 Bradford K, Shih DQ. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol 2011; 17(37): 4166-4173 [PMID: 22072847 DOI: 10.3748/wjg.v17.i37.4166] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 43] [Article Influence: 3.7] [Reference Citation Analysis]
315 Peyrin-Biroulet L, Fiorino G, Buisson A, Danese S. First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol 2013;10:345-51. [PMID: 23458890 DOI: 10.1038/nrgastro.2013.31] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
316 Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med 2011;8:e1001026. [PMID: 21559325 DOI: 10.1371/journal.pmed.1001026] [Cited by in Crossref: 182] [Cited by in F6Publishing: 161] [Article Influence: 16.5] [Reference Citation Analysis]
317 Osterman MT, Sandborn WJ, Colombel JF, Robinson AM, Lau W, Huang B, Pollack PF, Thakkar RB, Lewis JD. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology. 2014;146:941-949. [PMID: 24361468 DOI: 10.1053/j.gastro.2013.12.025] [Cited by in Crossref: 125] [Cited by in F6Publishing: 109] [Article Influence: 13.9] [Reference Citation Analysis]
318 Ferrante M, Karmiris K, Newnham E, Siffledeen J, Zelinkova Z, van Assche G, Lakatos PL, Panés J, Sturm A, Travis S, van der Woude CJ, Reinisch W, Colombel J, Panaccione R. Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme. Journal of Crohn's and Colitis 2012;6:116-31. [DOI: 10.1016/j.crohns.2011.09.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
319 O'Connor A, Qasim A, O'Moráin CA. The long-term risk of continuous immunosuppression using thioguanides in inflammatory bowel disease. Ther Adv Chronic Dis 2010;1:7-16. [PMID: 23251725 DOI: 10.1177/2040622310368736] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
320 Hudesman D, Lichtiger S, Sands B. Risk of extraintestinal solid cancer with anti-TNF therapy in adults with inflammatory bowel disease: review of the literature. Inflamm Bowel Dis 2013;19:644-9. [PMID: 23314243 DOI: 10.1097/MIB.0b013e318280ebbd] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
321 Beyaert R, Beaugerie L, Van Assche G, Brochez L, Renauld JC, Viguier M, Cocquyt V, Jerusalem G, Machiels JP, Prenen H, Masson P, Louis E, De Keyser F. Cancer risk in immune-mediated inflammatory diseases (IMID). Mol Cancer 2013;12:98. [PMID: 23987103 DOI: 10.1186/1476-4598-12-98] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 7.0] [Reference Citation Analysis]
322 Peyrin-Biroulet L, Colombel JF, Sandborn WJ. Insufficient evidence to conclude whether anti-tumor necrosis factor therapy increases the risk of lymphoma in Crohn's disease. Clin Gastroenterol Hepatol 2009;7:1139. [PMID: 19465159 DOI: 10.1016/j.cgh.2009.05.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]